KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...

Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...

Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma.

(Endpoints News) Bristol Myers Squibb and 2seventy bio announced discontinuation of enrollment in the phase III KarMMa-9 ...

Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma ...